SC 13G/A: Scinai Immunotherapeutics Ltd.

AI Summary

SC 13G/A filing by Scinai Immunotherapeutics Ltd..

Risk Assessment

Risk Level: low

FAQ

Filing Documents

• 13g.htm (SC 13G/A) — 34KB
• 0000912282-24-000580.txt ( ) — 35KB

(a). Name of Issuer

Item 1 (a). Name of Issuer: Scinai Immunotherapeutics Ltd. (the "Issuer")

(b). Address of Issuer's Principal Executive Offices

Item 1 (b). Address of Issuer's Principal Executive Offices: Jerusalem Biopark, 2 nd Floor Hadassah Ein Kerem Campus Jerusalem L3 00000

(a). Name of Person Filing

Item 2 (a). Name of Person Filing: Daniel E. Stone

(b). Address of Principal Business Office or, if None, Residence

Item 2 (b). Address of Principal Business Office or, if None, Residence: 1200 Brickell Avenue, #1470 Miami, FL 33131

(c). Citizenship

Item 2 (c). Citizenship: United States

(d). Title of Class of Securities

Item 2 (d). Title of Class of Securities: American Depositary Shares, each representing 4,000 Ordinary Shares, no par value

(e). CUSIP

Item 2 (e). CUSIP Number: 09073Q203 Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under Section 15 of the Act; (b) Bank as defined in Section 3(a)(6) of the Act; (c) Insurance Company as defined in Section 3(a)(19) of the Act; (d) Investment Company registered under Section 8 of the Investment Company Act; (e) Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F); (g) Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940: (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(j). X If this statement is filed pursuant to Rule 13d-1(c), check this box. Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1. (a) Amount beneficially owned: 62,400 (b) Percent of class: 7.4% (b) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 62,400 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 62,400 (iv) Shared power to dispose or to direct the disposition of: 0 The reporting person filed a Schedule 13G with respect to the reporting person's beneficial ownership of the securities on October 6, 2022, and amendments thereto on February 2, 2023, and January 24, 2024. On March 12, 2024, the reporting person amended the Schedule 13G by filing a Schedule 13D. This Amendment No. 3 to Schedule 13G, which updates the Schedule 13D, is being filed pursuant to Rule 13d-1(h). Instructi

Certification

Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. August 20, 2024 (Date) /s/ Daniel E. Stone Daniel E. Stone

View Full Filing

View this SC 13G/A filing on SEC EDGAR